Premier Biomedical (BIEI) 0.1300 $BIEI
Premier Biomedical Announces the Addition of K. Adam Dubov, Esq. to Scientific Advisory Board
Business Wire - Mon Sep 22, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI"
announced the addition of K. Adam Dubov to their Scientific Advisory Board effective immediately. Mr. Dubov will report to the Chairman of the Scientific Advisory Board, and co-founder of the Corporation, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman.
Premier Biomedical Announced the Addition of Dr David Vigerust to Their Scientific Advisory Board
GlobeNewswire - Mon Aug 18, 7:40AM CDT
Premier Biomedical, Inc. (OTC-BB: "BIEI" announced the addition of Dr David Vigerust to their Scientific Advisory Board effective immediately. Dr Vigerust will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder.
Premier Biotechnology & Anti-CTLA4
ACCESSWIRE - Mon Aug 18, 7:02AM CDT
Whitefish, MT / August 18, 2014 / Many forms of cancer are characterized by a lack of cellular apoptosis (e.g. cell death) and down-regulation of the immune system. In the case of the latter, cytotoxic T lymphocytes ("CTLs" are largely responsible for recognizing and killing cancer cells, but there are some inhibitory mechanisms that interrupt the destruction and prevents cancer cells from being targeted and destroyed.
Promising Medical Breakthroughs by Premier Biomedical, Inc.(BIEI)
GlobeNewswire - Tue Jul 29, 6:47AM CDT
Uptick Newswire sat with President and CEO of Premier Biomedical Inc., Mr. William A. Hartman, to get the scoop on their medical miracles that are stretching scientific limits. Based in El Paso Texas., Premier Biomedical Inc. is working closely with the US Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) in high hopes of creating a brighter future for those that have little hope of seeing that future today.
Premier Biomedical Gears Up for Two Important Clinical Trials
ACCESSWIRE - Fri Jul 25, 7:04AM CDT
Whitefish, MT / July 25, 2014 / Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative therapies targeting cancer, traumatic brain injury, Alzheimer's disease, MS and other serious conditions, recently announced that the William Beaumont Army Medical Center ("WBAMC" has begun drafting a protocol that it plans to submit to their Institutional Review Board overseeing its double-blind clinical trial of Feldetrex(tm) in mid-August.
Premier Biomedical, Inc. (BIEI) Retains Porter, LeVay and Rose as Investor Relations Council
GlobeNewswire - Thu Jul 24, 6:47AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI" a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer's disease, and other afflictions announced today that it has retained the investor relations firm Porter, LeVay and Rose to represent it and to implement its communications strategies.
Premier Biomedical, Inc. (BIEI) Announces Important Patent Award for a Potential Multi-Billion Dollar Drug for the Treatment of Fibromyalgia and Neuralgia
Business Wire - Mon Jun 30, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI" a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, Alzheimer's disease, multiple sclerosis (MS), traumatic brain injury (TBI), and others today announced that the United States Patent Office approved a patent on their proprietary medication "Feldetrex (TM)", which is designed to relieve the symptoms of neuropathic pain and fibromyalgia. The William Beaumont Army Medical Center Principal Investigator is drafting a protocol to conduct a double-blind, placebo-controlled comparison of this medication and the leading FDA-approved regimen for these concerns and will be submitting it for IRB approval in the near future.
Premier Biomedical Releases Anti-CTLA4 Market Study
Business Wire - Tue Jun 17, 7:02AM CDT
Premier Biomedical Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis ("MS" , and traumatic brain injury ("TBI" , today announced the release of a market study conducted by Penn Biotech Group Healthcare Consulting ("PBG" discussing its breast cancer treatment.
Premier Biomedical Continues Progress on Anti-Cancer Treatment
Business Wire - Wed Apr 02, 7:03AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has prepared and will file a provisional patent application for an anti-breast cancer treatment methodology protocol, in conjunction with its partners in R&D at the Department of Defense (DOD) with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) covering its study accepted for presentation at the American Association for Cancer Research (AACR) annual convention April 7-8, 2014 in San Diego. In addition, the group has discovered and will initiate an accelerated development program on two additional anti-cancer drug methodology protocols that it believes are unique in the industry and very promising.
Premier Biomedical to design clinical trial equipment in partnership with Printed Device Concepts
M2 - Thu Mar 27, 5:55AM CDT
Biopharmaceutical company Premier Biomedical (OTCBB:BIEI) revealed on Wednesday the launch of an agreement to design and fabricate its patent-pending Sequential Dialysis Machine that is critical to advancing its medications and procedures via anticipated clinical trials beginning as early as this calendar year.
Premier Biomedical Signs Agreement To Design Equipment For Clinical Trials
Business Wire - Wed Mar 26, 7:01AM CDT
Premier Biomedical, Inc., (OTCBB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has signed an agreement with Printed Device Concepts, Inc. (PDC) of El Paso, TX to design and fabricate a patent-pending Sequential Dialysis Machine that is critical to advancing the corporation's medications and procedures via anticipated clinical trials beginning as early as this calendar year. Premier has filed over a dozen pending provisional patent applications in the United States and the E.U. addressing a number of diseases previously regarded as incurable or "difficult", such as breast cancer, Alzheimer's disease, ALS, multiple sclerosis (MS), and traumatic brain injury (TBI). Design progress meetings between Premier Biomedical, Inc. (PBI) and Printed Device Concepts are being held coincident with PBI's other R&D partners, the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center (WBAMC) and the University of Texas at El Paso (UTEP).
Premier Biomedical Announces Payoff of Liabilities; Funding for Research and Development
Marketwire - Wed Mar 12, 7:16AM CDT
Premier Biomedical, Inc. (OTCQB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis (MS), and traumatic brain injury, announced today that through its equity funding arrangement with Kodiak Capital Group, LLC, which was announced in December 2013, it has paid all its liabilities and anticipates having sufficient capital to fund current on-going and mid-term research and development.
Premier Biomedical to Present Positive Pre-Clinical Breast Cancer Study at American Association for Cancer Research Annual Meeting
Marketwire - Wed Feb 26, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease and traumatic brain injury, announced today that Premier Biomedical will present significantly positive results from duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego, California on April 5-9, 2014. The results demonstrated statistically significant improvements in survival and a prevention of breast cancer in mice treated with Premier Biomedical's anti-breast cancer treatment compared to both chemotherapy and a non-treated control group.
Premier Biomedical Met With NFL and NCAA Representatives During Super Bowl Week at Coalition for Concussion Treatment Summit at the United Nations
Marketwire - Thu Feb 13, 7:15AM CST
Premier Biomedical, Inc. (http://www.premierbiomedical.com/) (OTCQB: BIEI) today released the following statement regarding their participation in the Coalition for Concussion Treatment (#C4CT) Summit established by Brewer Sports International (http://www.brewersports.com/) (BSI) during Super Bowl Week at the United Nations Headquarters in New York City. The conference followed the announcement that Brewer Sports International and Premier Biomedical have entered into a long-term strategic partnership agreement to continue to explore innovative treatment methods for Traumatic Brain Injury (TBI) and other neurological diseases.
CEO CFO Magazine Interviews Premier Biomedical's CEO Hartman; Second Time in 16 Months
Marketwire - Tue Feb 11, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) (OTCBB: BIEI) today announced that President and Chief Executive Officer, William A. Hartman, was recently interviewed for a second time in 16 months by CEO/CFO Magazine, an independent investment publication which conducts interviews with company CEOs. The latest William Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (570) 851-1745 or via CEO/CFO Magazine Online (http://www.ceocfointerviews.com). (The original interview was in the October, 2012 edition.)
Premier Biomedical Advances Vs Head Trauma
Marketwire - Wed Jan 22, 7:02AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) today released the following statement regarding advances in the treatment of Head Trauma. There has been considerable news lately related to professional sports and the incidence rate of head trauma, also referred to as Traumatic Brain Injury, and its lasting effects on clinical depression, suicide/violence ideation, PTSD and longer term, persistent neurological diseases such as Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis (ALS). The scope of the problem is revealed by lesser known statistics published by the Veterans Administration, indicating suicide rates among active-duty personnel are almost one per day. If we include veterans, the number of suicides jumps to almost ONE PER HOUR. This is a huge morale problem and one that demands our collective utmost attention.
MTS Systems and Chery Automobile Company Celebrate The Opening of Their Joint Vehicle System Engineering Laboratory In China
PR Newswire - Thu Jan 09, 5:40PM CST
MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems and position sensors, today announced the grand opening of a vehicle system engineering laboratory in collaboration with Chery Automobile Co. Ltd. in Wuhu, China. The first MTS joint laboratory with a domestic Chinese automotive OEM, the Chery-MTS lab is a center for system and full-vehicle testing applications, as well as the development of new testing technologies.
Premier Biomedical, Inc. Expands Intellectual Property for Multiple Sclerosis
ACCESSWIRE - Thu Aug 22, 7:05AM CDT
El Paso, TX, August 22, 2013 - (Accesswie) - Premier Biomedical, Inc. (OTCQB: BIEI) (http://www.premierbiomedical.com/), today announced that the company is pursuing an international patent application for its core technology to treat multiple sclerosis (MS). Development of Premier's therapy, which is functionally similar to its technology for traumatic brain injury, cancer, and Alzheimer's disease, is anticipated to occur through the company's existing research channels. Premier has already registered its technology behind multiple provisional patents in the United States and a Europe National Patent in the areas of cancer, blood sepsis, and Alzheimer's disease. In total, the company holds nine provisional patent applications and six international patent applications.
Premier Biomedical Announces the Addition of K. Adam Dubov, Esq. to Scientific Advisory Board
Business Wire - Mon Sep 22, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI"
announced the addition of K. Adam Dubov to their Scientific Advisory Board effective immediately. Mr. Dubov will report to the Chairman of the Scientific Advisory Board, and co-founder of the Corporation, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman. Premier Biomedical Announced the Addition of Dr David Vigerust to Their Scientific Advisory Board
GlobeNewswire - Mon Aug 18, 7:40AM CDT
Premier Biomedical, Inc. (OTC-BB: "BIEI"
announced the addition of Dr David Vigerust to their Scientific Advisory Board effective immediately. Dr Vigerust will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder. Premier Biotechnology & Anti-CTLA4
ACCESSWIRE - Mon Aug 18, 7:02AM CDT
Whitefish, MT / August 18, 2014 / Many forms of cancer are characterized by a lack of cellular apoptosis (e.g. cell death) and down-regulation of the immune system. In the case of the latter, cytotoxic T lymphocytes ("CTLs"
are largely responsible for recognizing and killing cancer cells, but there are some inhibitory mechanisms that interrupt the destruction and prevents cancer cells from being targeted and destroyed. Promising Medical Breakthroughs by Premier Biomedical, Inc.(BIEI)
GlobeNewswire - Tue Jul 29, 6:47AM CDT
Uptick Newswire sat with President and CEO of Premier Biomedical Inc., Mr. William A. Hartman, to get the scoop on their medical miracles that are stretching scientific limits. Based in El Paso Texas., Premier Biomedical Inc. is working closely with the US Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) in high hopes of creating a brighter future for those that have little hope of seeing that future today.
Premier Biomedical Gears Up for Two Important Clinical Trials
ACCESSWIRE - Fri Jul 25, 7:04AM CDT
Whitefish, MT / July 25, 2014 / Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative therapies targeting cancer, traumatic brain injury, Alzheimer's disease, MS and other serious conditions, recently announced that the William Beaumont Army Medical Center ("WBAMC"
has begun drafting a protocol that it plans to submit to their Institutional Review Board overseeing its double-blind clinical trial of Feldetrex(tm) in mid-August. Premier Biomedical, Inc. (BIEI) Retains Porter, LeVay and Rose as Investor Relations Council
GlobeNewswire - Thu Jul 24, 6:47AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI"
a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer's disease, and other afflictions announced today that it has retained the investor relations firm Porter, LeVay and Rose to represent it and to implement its communications strategies. Premier Biomedical, Inc. (BIEI) Announces Important Patent Award for a Potential Multi-Billion Dollar Drug for the Treatment of Fibromyalgia and Neuralgia
Business Wire - Mon Jun 30, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: "BIEI"
a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, Alzheimer's disease, multiple sclerosis (MS), traumatic brain injury (TBI), and others today announced that the United States Patent Office approved a patent on their proprietary medication "Feldetrex (TM)", which is designed to relieve the symptoms of neuropathic pain and fibromyalgia. The William Beaumont Army Medical Center Principal Investigator is drafting a protocol to conduct a double-blind, placebo-controlled comparison of this medication and the leading FDA-approved regimen for these concerns and will be submitting it for IRB approval in the near future. Premier Biomedical Releases Anti-CTLA4 Market Study
Business Wire - Tue Jun 17, 7:02AM CDT
Premier Biomedical Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis ("MS"
, and traumatic brain injury ("TBI" , today announced the release of a market study conducted by Penn Biotech Group Healthcare Consulting ("PBG" discussing its breast cancer treatment. Premier Biomedical Continues Progress on Anti-Cancer Treatment
Business Wire - Wed Apr 02, 7:03AM CDT
Premier Biomedical, Inc. (OTCBB:BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has prepared and will file a provisional patent application for an anti-breast cancer treatment methodology protocol, in conjunction with its partners in R&D at the Department of Defense (DOD) with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) covering its study accepted for presentation at the American Association for Cancer Research (AACR) annual convention April 7-8, 2014 in San Diego. In addition, the group has discovered and will initiate an accelerated development program on two additional anti-cancer drug methodology protocols that it believes are unique in the industry and very promising.
Premier Biomedical to design clinical trial equipment in partnership with Printed Device Concepts
M2 - Thu Mar 27, 5:55AM CDT
Biopharmaceutical company Premier Biomedical (OTCBB:BIEI) revealed on Wednesday the launch of an agreement to design and fabricate its patent-pending Sequential Dialysis Machine that is critical to advancing its medications and procedures via anticipated clinical trials beginning as early as this calendar year.
Premier Biomedical Signs Agreement To Design Equipment For Clinical Trials
Business Wire - Wed Mar 26, 7:01AM CDT
Premier Biomedical, Inc., (OTCBB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies, has signed an agreement with Printed Device Concepts, Inc. (PDC) of El Paso, TX to design and fabricate a patent-pending Sequential Dialysis Machine that is critical to advancing the corporation's medications and procedures via anticipated clinical trials beginning as early as this calendar year. Premier has filed over a dozen pending provisional patent applications in the United States and the E.U. addressing a number of diseases previously regarded as incurable or "difficult", such as breast cancer, Alzheimer's disease, ALS, multiple sclerosis (MS), and traumatic brain injury (TBI). Design progress meetings between Premier Biomedical, Inc. (PBI) and Printed Device Concepts are being held coincident with PBI's other R&D partners, the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center (WBAMC) and the University of Texas at El Paso (UTEP).
Premier Biomedical Announces Payoff of Liabilities; Funding for Research and Development
Marketwire - Wed Mar 12, 7:16AM CDT
Premier Biomedical, Inc. (OTCQB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis (MS), and traumatic brain injury, announced today that through its equity funding arrangement with Kodiak Capital Group, LLC, which was announced in December 2013, it has paid all its liabilities and anticipates having sufficient capital to fund current on-going and mid-term research and development.
Premier Biomedical to Present Positive Pre-Clinical Breast Cancer Study at American Association for Cancer Research Annual Meeting
Marketwire - Wed Feb 26, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease and traumatic brain injury, announced today that Premier Biomedical will present significantly positive results from duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego, California on April 5-9, 2014. The results demonstrated statistically significant improvements in survival and a prevention of breast cancer in mice treated with Premier Biomedical's anti-breast cancer treatment compared to both chemotherapy and a non-treated control group.
Premier Biomedical Met With NFL and NCAA Representatives During Super Bowl Week at Coalition for Concussion Treatment Summit at the United Nations
Marketwire - Thu Feb 13, 7:15AM CST
Premier Biomedical, Inc. (http://www.premierbiomedical.com/) (OTCQB: BIEI) today released the following statement regarding their participation in the Coalition for Concussion Treatment (#C4CT) Summit established by Brewer Sports International (http://www.brewersports.com/) (BSI) during Super Bowl Week at the United Nations Headquarters in New York City. The conference followed the announcement that Brewer Sports International and Premier Biomedical have entered into a long-term strategic partnership agreement to continue to explore innovative treatment methods for Traumatic Brain Injury (TBI) and other neurological diseases.
CEO CFO Magazine Interviews Premier Biomedical's CEO Hartman; Second Time in 16 Months
Marketwire - Tue Feb 11, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) (OTCBB: BIEI) today announced that President and Chief Executive Officer, William A. Hartman, was recently interviewed for a second time in 16 months by CEO/CFO Magazine, an independent investment publication which conducts interviews with company CEOs. The latest William Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (570) 851-1745 or via CEO/CFO Magazine Online (http://www.ceocfointerviews.com). (The original interview was in the October, 2012 edition.)
Premier Biomedical Advances Vs Head Trauma
Marketwire - Wed Jan 22, 7:02AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) today released the following statement regarding advances in the treatment of Head Trauma. There has been considerable news lately related to professional sports and the incidence rate of head trauma, also referred to as Traumatic Brain Injury, and its lasting effects on clinical depression, suicide/violence ideation, PTSD and longer term, persistent neurological diseases such as Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis (ALS). The scope of the problem is revealed by lesser known statistics published by the Veterans Administration, indicating suicide rates among active-duty personnel are almost one per day. If we include veterans, the number of suicides jumps to almost ONE PER HOUR. This is a huge morale problem and one that demands our collective utmost attention.
MTS Systems and Chery Automobile Company Celebrate The Opening of Their Joint Vehicle System Engineering Laboratory In China
PR Newswire - Thu Jan 09, 5:40PM CST
MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems and position sensors, today announced the grand opening of a vehicle system engineering laboratory in collaboration with Chery Automobile Co. Ltd. in Wuhu, China. The first MTS joint laboratory with a domestic Chinese automotive OEM, the Chery-MTS lab is a center for system and full-vehicle testing applications, as well as the development of new testing technologies.
Premier Biomedical, Inc. Expands Intellectual Property for Multiple Sclerosis
ACCESSWIRE - Thu Aug 22, 7:05AM CDT
El Paso, TX, August 22, 2013 - (Accesswie) - Premier Biomedical, Inc. (OTCQB: BIEI) (http://www.premierbiomedical.com/), today announced that the company is pursuing an international patent application for its core technology to treat multiple sclerosis (MS). Development of Premier's therapy, which is functionally similar to its technology for traumatic brain injury, cancer, and Alzheimer's disease, is anticipated to occur through the company's existing research channels. Premier has already registered its technology behind multiple provisional patents in the United States and a Europe National Patent in the areas of cancer, blood sepsis, and Alzheimer's disease. In total, the company holds nine provisional patent applications and six international patent applications.
